Changes in use of 17-OHPC after the PROLONG trial: a physician survey
| Autor: | Itamar D. Futterman, Laura Gilroy, Nawras Zayat, Kimen Balhotra, Jeremy Weedon, Howard Minkoff |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of Perinatal Medicine. |
| ISSN: | 1619-3997 0300-5577 |
| Popis: | Objectives To determine if 17α-hydroxyprogesterone caproate (17OHPC) or vaginal progesterone use for patients at risk for preterm birth has changed since the publication of the 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG) trial, and to assess which organizations’ (Food and Drug Administration’s [FDA], American College of Obstetrics and Gynecology’s [ACOG] or Society of Maternal Fetal Medicine’s [SMFM]) statements most influenced change. Methods Through a vignette-based physician survey, we sought to measure (by Likert scale) how counseling tendencies regarding 17OHPC and vaginal progesterone have changed since the PROLONG trial publication. Participants were also asked which organizations’ statements most influenced change. Results With response rate of 97 % (141/145), a pre-to-post PROLONG trial comparison revealed significant changes in counseling for progesterone. Respondents were less likely to recommend 17OHPC (pr=−0.23, p=0.005). Conclusions Providers have made significant changes in their counseling regarding progesterone use for patients at risk for preterm birth after the publication of the PRLONG trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|